The Association between Hemodynamically Significant Patent Ductus Arteriosus and 25-Hydroxyvitamin D Levels in Preterm Infants ≤32 Weeks Gestational Age

Abstract

Introduction

We investigated the relationship between 25-hydroxyvitamin D (25-OHD) levels and the development of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants.

Methods

Newborns having a gestational age (GA) of ≤32 weeks with hsPDA consisted the study group (n = 25, 20%), while newborns ≤32 weeks of GA without PDA/hsPDA were the control group (n = 97, 80%).

Results

The study group had lower GA, birth weight (BW) and 25-OHD levels (p < 0.0001, p = 0.002 and p = 0.003, respectively). After adjusting for the effects of GA, BW and the presence of respiratory distress syndrome, multivariable logistic regression analyses demonstrated that preterm infants with low 25-OHD levels were 6.407 (95% CI: 1.656–24.788, p = 0.007) times more likely to experience hsPDA than preterm infants with normal 25-OHD levels. Every 1 ng/mL increase in 25-OHD levels decreased the probability of hsPDA (OR: 0.894, 95% CI: 0.816–0.98, p = 0.016). Conclusion: Low 25-OHD levels may have a role in the development of hsPDA.

Keywords:

• Hemodynamically significant patent ductus arteriosus
• 25-hydroxyvitamin D
• calcium
• premature infant

Data availability

The data that support the findings of this study are available on request from the corresponding author, EB. The data are not publicly available due to restrictions e.g. their containing information that could compromise the privacy of research participants.

Disclosure statement

The authors declare that they have no conflicts of interest with the contents of this article.

Additional information

Funding

The authors declared that this study received no financial support.